Carbonic anhydrase IX (CAIX) (CAIX)

Carbonic anhydrase IX (CAIX) is a transmembrane zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, playing a critical role in pH homeostasis [1]. It is highly overexpressed in various solid tumors, most notably clear cell renal cell carcinoma (ccRCC), under the control of the hypoxia-inducible factor 1-alpha (HIF-1α) [2]. In the tumor microenvironment, CAIX-mediated extracellular acidification facilitates tumor cell survival, invasion, and metastasis while contributing to therapeutic resistance [3]. Because CAIX expression is largely restricted to the gastrointestinal tract in healthy individuals, it is considered an ideal target for tumor-specific therapies [1]. Therapeutic strategies include monoclonal antibodies like girentuximab, which induce antibody-dependent cellular cytotoxicity (ADCC), and peptide vaccines such as those derived from the G250 antigen to stimulate T-cell mediated immunity [4][5]. Small molecule inhibitors are also being developed to block the enzymatic activity of CAIX, thereby disrupting the pH gradient necessary for tumor progression [6].

Other names

G250MNCA9Carbonate dehydratase IXRenal cell carcinoma-associated antigen G250

CAIX is targeted through multiple modalities: monoclonal antibodies (e.g., girentuximab) bind the extracellular domain to trigger antibody-dependent cellular cytotoxicity (ADCC); peptide vaccines (e.g., G250-based) are processed and presented by MHC molecules to induce specific CD8+ T-cell responses; and small molecule inhibitors bind the zinc-containing catalytic site to inhibit pH regulation [3][4][6].